Jacobs Levy Equity Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Jacobs Levy Equity Management’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-625,568	Closed	-$1.73M	–	1163
2021 Q1	$1.73M	Buy	625,568 +194,867	+45%	+$588K	0.01%	631
2020 Q4	$1.05M	Buy	430,701 +123,088	+40%	+$297K	0.01%	712
2020 Q3	$646K	Sell	307,613 -17,671	-5%	-$59.6K	0.01%	742
2020 Q2	$1.23M	Buy	325,284 +128,636	+65%	+$385K	0.01%	632
2020 Q1	$372K	Buy	+196,648	New	+$511K	﹤0.01%	799

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Jacobs Levy Equity Management's SBBP Position: Q2 2021 in Review

Jacobs Levy Equity Management sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2021, closing a stake of 625,568 shares — an estimated $1.73M sold.

Jacobs Levy Equity Management first reported a position in SBBP in Q1 2020 and held it in 5 quarters. The position peaked at $1.73M in Q1 2021. 60 funds tracked by Wall St. Rank hold SBBP as of Q2 2021.

Jacobs Levy Equity Management reported no remaining Strongbridge Biopharma plc. position as of Q2 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 625,568 Strongbridge Biopharma plc. shares in Q2 2021, an estimated $1.73M.
Jacobs Levy Equity Management first reported a position in Strongbridge Biopharma plc. in Q1 2020 and held it in 5 quarters.
Jacobs Levy Equity Management's Strongbridge Biopharma plc. position peaked at $1.73M in Q1 2021.
60 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.